AstraZeneca’s Triple Regulatory Wins For Enhertu, Tezspire And Ultomiris Herald Sales Boost
Across US And EU
The major has won US priority review for a commercially crucial label expansion of its breast cancer drug Enhertu while Tezspire and Ultomiris attracted positive CHMP opinions across the Atlantic.
You may also be interested in...
AstraZeneca’s momentum is growing towards ‘industry-leading' revenue growth, but investors are focused on the operating margin, and concerned about when CEO Pascal Soriot will depart.
The results of DESTINY-Breast04 could impact survival for approximately 50% of patients diagnosed with metastatic breast cancer today, principal investigator Modi said at the American Society of Clinical Oncology annual meeting.
The generalized myasthenia gravis-approved drug passed the $20m mark in sales for the first quarter, comfortably surpassing analyst estimates.